1. Vías de señalización
  2. Neuronal Signaling
  3. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Nombre del producto Efecto Pureza Chemical Structure
  • HY-W111226
    Fmoc-His(3-Me)-OH
    Inhibitor 99.67%
    Fmoc-His (3-Me)-OH is a histidine derivative with a methylated imidazole group. Fmoc-His (3-Me)-OH can be used for the synthesis of the chemically modified tripeptide His (3-methyl)-Arg-Trp (H (3-Me)-RW). Fmoc-His (3-Me)-OH serves as a resin in Fmoc solid-phase synthesis for the generation of the His-(3-Me)-Gly-Lys peptide. Fmoc-His (3-Me)-OH is a building block for the synthesis of NAHIS02-(p-Met). Fmoc-His (3-Me)-OH can be applied in research related to Alzheimer's disease.
    Fmoc-His(3-Me)-OH
  • HY-P1466
    β-Amyloid (1-16)
    99.98%
    β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.
    β-Amyloid (1-16)
  • HY-W127558
    Cholesterol-PEG 600
    Cholesterol-PEG 600 is a synthetic cholesterol derivative and also a Aβ (1-42) binder. Cholesterol-PEG 600 promotes the fibrillogenesis of Aβ (1-42). Cholesterol-PEG 600 is applicable to the research of Alzheimer's disease.
    Cholesterol-PEG 600
  • HY-14503
    MDR-1339
    Inhibitor 99.95%
    MDR-1339 (DWK-1339) is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer's disease.
    MDR-1339
  • HY-B0914A
    10-Undecenoic acid zinc salt
    Inhibitor 98.0%
    10-Undecenoic acid zinc salt (Undecylenic acid zinc salt) is an antifungal agent. 10-Undecenoic acid zinc salt inhibits oligomerization, scavenges ROS and inhibits μ-calpain activity. 10-Undecenoic acid zinc salt has neuroprotective effects. 10-Undecenoic acid zinc salt has anticancer effects on a variety of tumors. 10-Undecenoic acid zinc salt inhibits C. albicans biofilm formation and MRSA infection. 10-Undecenoic acid zinc salt inhibits quorum sensing signals of Bacillus subtilis and Pseudomonas aeruginosa.
    10-Undecenoic acid zinc salt
  • HY-148495
    Carnosine conjugated hyalyronate
    Inhibitor
    Carnosine conjugated hyalyronate is a hyaluronic acid derivative functionalized with the dipeptide carnosine (Carnosine, Car) and has the ability to resist amyloid aggregation. Carnosine conjugated hyalyronate dissolves amyloid fibrils and reduces Aβ-induced toxicity in vitro. The effectiveness of Carnosine conjugated hyalyronate against amyloid aggregation is directly proportional to the Carnosine loading.
    Carnosine conjugated hyalyronate
  • HY-176040
    IXA62
    Inhibitor 99.55%
    IXA62 is an orally active and selective IRE1/XBP1s activator (EC50 = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells.
    IXA62
  • HY-W014589R
    2,4-Di-tert-butylphenol (Standard)
    Inhibitor
    2,4-Di-tert-butylphenol (Standard) is the analytical standard of 2,4-Di-tert-butylphenol (HY-W014589). This product is intended for research and analytical applications. 2,4-Di-tert-butylphenol (2,4-DTBP) is an orally active RXRα activator and a human estrogen receptor ligand with anti-inflammatory and antioxidant activities, which can induce apoptosis in tumor cells. 2,4-Di-tert-butylphenol can activate the RXRα subtype in LXRα/RXRα, PPARγ/RXRα, and hormone receptor β/RXRα. 2,4-Di-tert-butylphenol also has antiviral and antifungal activities, and has the potential to inhibit -induced neurotoxicity. 2,4-Di-tert-butylphenol can be used as an intermediate in the preparation of antioxidants and UV stabilizers, and is also used in the manufacture of pharmaceuticals and fragrances.
    2,4-Di-tert-butylphenol (Standard)
  • HY-103442
    CGP52411
    Inhibitor 99.82%
    CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive EGFR inhibitor with an IC50 of 0.3 μM. CGP52411 blocks the toxic influx of Ca2+ ions into neuronal cells, and dramatic inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates associated with Alzheimer's disease.
    CGP52411
  • HY-P991480
    ONC-841
    Inhibitor
    ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of Amyloid-β and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease.
    ONC-841
  • HY-15374
    Frentizole
    Inhibitor 98.48%
    Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC50 value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus.
    Frentizole
  • HY-P99216
    Ponezumab
    Inhibitor
    Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease.
    Ponezumab
  • HY-W143216
    Azure C
    Inhibitor
    Azure C acts as a tau oligomer modulator and Aβ42 oligomerization inhibitor. It regulates hsp70 ATPase activity, thereby mediating the clearance of tau protein. Azure C reduces the levels of toxic tau oligomers by promoting the formation of non-toxic tau aggregates, rescues neuroblastoma cells from tau oligomer-induced toxicity, and binds to and inhibits Aβ42 oligomerization without suppressing its fibrillization. Azure C is generated via sequential oxidation of methylene blue or Azure B through a horseradish peroxidase-mediated reaction, and accumulates in HRP reaction media. Azure C can be used in studies related to tauopathies, including Alzheimer's disease.
    Azure C
  • HY-163575
    ACI-19626
    Ligand 98.52%
    ACI-19626 (TDP-43-IN-2) is a TDP-43 aggregation inhibitor that can be used in the research of neurodegenerative diseases.
    ACI-19626
  • HY-16632
    ELND 006
    Inhibitor 99.7%
    ELND 006 (Compound 30) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Aβ levels in vitro and in vivo. Comparisons with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Aβ levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimer's disease.
    ELND 006
  • HY-103374
    Phenserine
    Inhibitor 99.55%
    Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease.
    Phenserine
  • HY-P2268A
    RAGE antagonist peptide TFA
    Antagonist 99.41%
    RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities.
    RAGE antagonist peptide TFA
  • HY-B1588
    Carbenoxolone
    Inhibitor 99.99%
    Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.
    Carbenoxolone
  • HY-17631A
    Edonerpic maleate
    Inhibitor 99.79%
    Edonerpic maleate is a novel neurotrophic agent which can inhibit amyloid-β peptides ().
    Edonerpic maleate
  • HY-139142
    Simufilam
    Inhibitor 99.78%
    Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam can be used for research of Alzheimer's disease.
    Simufilam
Cat. No. Nombre del producto / Synonyms Application Reactivity